Gold nanoplasmonic chip tracks L-DOPA response in Parkinson's 'mini-brains'

edited by Sadie Harley , reviewed by Robert Egan

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

Add as preferred source Nanoplasmonic organoid-on-a-chip platform. Credit: ACS Nano (2026). DOI: 10.1021/acsnano.6c09629 Researchers have developed an organoid-on-a-chip technology that verifies the efficacy of Parkinson's disease treatments in real time. The technology combines a stem cell–derived "mini-brain" with a nanoplasmonic sensor engineered to maximize light–matter interaction.

An organoid is a "three-dimensional mini-organ" grown from human stem cells to closely resemble an actual organ. The research team created an organoid modeled after the brainstem, the core region connecting the brain and spinal cord that regulates functions such as breathing and movement.

Parkinson's disease is a neurodegenerative disorder in which damage to dopamine-secreting cells—which transmit motor signals in the brain—causes tremors and muscle rigidity.